Skip to main content

07-02-2022 | Image

Timeline of JAK inhibitor approvals for rheumatic diseases in the USA and Europe

AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis. *in patients with an inadequate response or intolerance to at least one tumor necrosis factor inhibitor.

print
PRINT